Thermo Fisher Scientific (TMO) Competitors

$575.10
+26.72 (+4.87%)
(As of 04/23/2024 ET)

TMO vs. AZN, NVS, ABT, PFE, AMGN, ISRG, SYK, ELV, SNY, and ABBV

Should you be buying Thermo Fisher Scientific stock or one of its competitors? The main competitors of Thermo Fisher Scientific include AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), Amgen (AMGN), Intuitive Surgical (ISRG), Stryker (SYK), Elevance Health (ELV), Sanofi (SNY), and AbbVie (ABBV). These companies are all part of the "medical" sector.

Thermo Fisher Scientific vs.

AstraZeneca (NASDAQ:AZN) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.

AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.7%. Thermo Fisher Scientific pays an annual dividend of $1.56 per share and has a dividend yield of 0.3%. AstraZeneca pays out 100.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Thermo Fisher Scientific pays out 10.1% of its earnings in the form of a dividend. AstraZeneca has raised its dividend for 1 consecutive years and Thermo Fisher Scientific has raised its dividend for 7 consecutive years.

AstraZeneca presently has a consensus target price of $80.00, indicating a potential upside of 12.91%. Thermo Fisher Scientific has a consensus target price of $604.69, indicating a potential upside of 5.14%. Given Thermo Fisher Scientific's higher possible upside, research analysts plainly believe AstraZeneca is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Thermo Fisher Scientific
0 Sell rating(s)
5 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.69

AstraZeneca has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Thermo Fisher Scientific has a net margin of 13.99% compared to Thermo Fisher Scientific's net margin of 13.00%. Thermo Fisher Scientific's return on equity of 30.19% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca13.00% 30.19% 11.57%
Thermo Fisher Scientific 13.99%18.78%8.70%

In the previous week, AstraZeneca had 4 more articles in the media than Thermo Fisher Scientific. MarketBeat recorded 19 mentions for AstraZeneca and 15 mentions for Thermo Fisher Scientific. AstraZeneca's average media sentiment score of 1.01 beat Thermo Fisher Scientific's score of 0.55 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
8 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
10 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Thermo Fisher Scientific has lower revenue, but higher earnings than AstraZeneca. AstraZeneca is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca$45.81B4.80$5.96B$1.9236.90
Thermo Fisher Scientific$42.86B5.12$6.00B$15.4537.22

20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Thermo Fisher Scientific received 996 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 81.13% of users gave Thermo Fisher Scientific an outperform vote while only 57.61% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
AstraZenecaOutperform Votes
53
57.61%
Underperform Votes
39
42.39%
Thermo Fisher ScientificOutperform Votes
1049
81.13%
Underperform Votes
244
18.87%

Summary

Thermo Fisher Scientific beats AstraZeneca on 15 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMO vs. The Competition

MetricThermo Fisher ScientificMeasuring & controlling devices IndustryMedical SectorNYSE Exchange
Market Cap$209.32B$19.14B$4.84B$17.45B
Dividend Yield0.29%3.50%5.51%3.59%
P/E Ratio37.2223.39244.6425.24
Price / Sales5.1221.052,531.6710.31
Price / Cash17.8813.9032.1614.95
Price / Book4.763.724.685.01
Net Income$6.00B$536.75M$102.44M$963.51M
7 Day Performance5.09%0.96%0.41%2.52%
1 Month Performance-1.37%-9.45%-5.79%-1.85%
1 Year Performance0.14%22.78%10.14%90.34%

Thermo Fisher Scientific Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
3.3645 of 5 stars
$70.85
+1.0%
$80.00
+12.9%
-6.3%$219.67B$45.81B36.9089,900Upcoming Earnings
NVS
Novartis
2.6968 of 5 stars
$97.29
+2.3%
$114.00
+17.2%
-3.0%$198.86B$45.44B13.5576,057Analyst Revision
News Coverage
Gap Up
High Trading Volume
ABT
Abbott Laboratories
4.995 of 5 stars
$107.57
+0.5%
$121.80
+13.2%
-3.7%$186.65B$40.11B33.51114,000Earnings Report
Analyst Report
Analyst Revision
PFE
Pfizer
4.9942 of 5 stars
$26.32
+0.2%
$36.33
+38.0%
-34.5%$149.04B$58.50B73.1188,000Upcoming Earnings
AMGN
Amgen
4.7854 of 5 stars
$273.54
+0.6%
$296.95
+8.6%
+12.2%$146.72B$28.19B21.9026,700
ISRG
Intuitive Surgical
4.6862 of 5 stars
$377.08
+2.2%
$396.17
+5.1%
+25.6%$133.66B$7.12B68.0713,676Earnings Report
SYK
Stryker
4.7823 of 5 stars
$334.89
+2.2%
$340.67
+1.7%
+10.3%$127.42B$20.50B40.5952,000Upcoming Earnings
ELV
Elevance Health
4.8377 of 5 stars
$532.92
+0.1%
$587.64
+10.3%
+18.2%$123.86B$171.34B20.14104,900Earnings Report
Dividend Announcement
Analyst Revision
SNY
Sanofi
3.0788 of 5 stars
$47.69
+1.1%
$55.00
+15.3%
-15.9%$120.64B$46.61B20.2186,088Upcoming Earnings
ABBV
AbbVie
4.9288 of 5 stars
$169.54
+1.0%
$177.43
+4.7%
+4.4%$300.20B$54.32B62.1050,000Upcoming Earnings

Related Companies and Tools

This page (NYSE:TMO) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners